AstraZeneca PLC — Regulatory Filings 2016

Nov 17, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1. AZ out-licensing deal with Allergan completed dated 17th November 2016

17 November 2016 07:00

MEDIMMUNE COMPLETES OUT-LICENSING

AGREEMENT WITH ALLERGAN FOR MEDI2070

AstraZeneca today announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.

MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn's disease and ready for Phase II for ulcerative colitis, diseases that sit outside AstraZeneca's three main therapy areas .

AstraZeneca will not retain a significant ongoing interest in MEDI2070. Therefore, income from the transaction will be reported as Other Operating Income in the Company's financial statements, including the upfront payment, which will be booked in the fourth quarter of 2016, and development and sales-related milestones and tiered royalties on potential sales of the medicine.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & M e tabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

| Media
Enquiries — Neil
Burrows | UK/Global | +44 203
749 5637 |
| --- | --- | --- |
| Vanessa
Rhodes | UK/Global | +44 203
749 5736 |
| Karen
Birmingham | UK/Global | +44 203
749 5634 |
| Rob
Skelding | UK/Global | +44 203
749 5821 |
| Jacob
Lund | Sweden | +46
8 553 260 20 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor
Relations | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Craig
Marks | Finance,
Fixed Income, M&A | +44
7881 615 764 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Mitchell
Chan | Oncology | +1 240
477 3771 |
| Lindsey
Trickett | Cardiovascular
& Metabolic Diseases | +1 240
543 7970 |
| Nick
Stone | Respiratory | +44 203
749 5716 |
| Christer
Gruvris | Autoimmunity,
neuroscience & infection | +44 203
749 5711 |
| US toll
free | | +1 866
381 7277 |

Adrian Kemp

Company Secretary, AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

| Date:
17 November 2016 |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |